Mr. Doug Drysdale reports

CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB004 PROGRAM IN PHASE 2 DEVELOPMENT FOR GENERALIZED ANXIETY DISORDER

The United States Patent and Trademark Office has granted United States patent 12,318,477 in support of Cybin Inc.'s CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder (GAD).

The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular (IM) injection, including CYB004.

"Patents are extremely valuable assets, and protection for our lead product candidates is a top priority for us," said Doug Drysdale, chief executive officer of Cybin. "We believe that our CYB004 program has the potential to deliver short-duration, rapid-acting treatment for anxiety disorders and offer more patient-friendly dosing methods such as IM administration. The issuance of this additional patent in support of CYB004 adds further validation of this important program. Dosing is currently under way in our phase 2 study evaluating CYB004 in generalized anxiety disorder, and we expect the study to complete around mid year. I'm proud that Cybin has amassed one of the strongest IP portfolios in the sector with more than 90 granted patents and over 230 pending applications."

About Cybin Inc.

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long-lasting results. The company is currently developing CYB003, a proprietary deuterated psilocin program, in phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

We seek Safe Harbor.